Today, a Major Shareholder at CareDx (NASDAQ: CDNA), Neil Gagnon, sold shares of CDNA for $2.94M.
This is Gagnon’s first Sell trade following 34 Buy transactions. Following Neil Gagnon’s last CDNA Sell transaction on April 30, 2018, the stock climbed by 17.5%.
See today’s analyst top recommended stocks >>
Based on CareDx’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $17.82 million and GAAP net loss of $14.06 million. In comparison, last year the company earned revenue of $12.19 million and had a GAAP net loss of $14.27 million. The Company has a Price to Book ratio of 33.8979. Currently, CareDx has an average volume of 434K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $23.33, reflecting a -15.0% downside.
The insider sentiment on CareDx has been neutral according to 53 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions.
